X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

IP Explained: Why patents are so critical to biopharmaceutical innovation

By Tom Wilbur  |    April 16, 2019
Today, we are excited to launch our new IP Explained Catalyst series, where each week we’ll break down critical components of the intellectual property (IP) system and the important role it plays...   Read More

Special 301 submission calls for a level playing field for American innovators

By Megan Van Etten  |    March 13, 2019
The Office of the U.S. Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market...   Read More

Celebrating U.S. innovation as USPTO issues the 10 millionth patent

By Nicole Longo  |    June 19, 2018
The U.S. patent system has supported innovation and discovery dating back to the founding of our nation and the signing of the U.S. Constitution, encouraging Americans to continue to search for...   Read More

Supreme Court decisions in two cases pave way for IPR reforms

By Nicole Longo  |    May 31, 2018
At the end of April, the Supreme Court decided two cases concerning the inter partes review (IPR) proceedings enacted as part of the 2011 America Invents Act (AIA). While distinct cases, together...   Read More

What is inter partes review and why does it matter?

By Nicole Longo  |    March 16, 2018
For more than three decades Hatch-Waxman (the Drug Price Competition and Patent Term Restoration Act of 1984) has encouraged innovation in biopharmaceutical development while at the same time...   Read More

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

By Mark Grayson  |    May 5, 2017
America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property...   Read More

Illegal trade barriers discriminate against U.S. innovators

By Jay Taylor  |    May 2, 2017
America has long led the world in medical innovation – which brings breakthrough, lifesaving medicines to people around the world, and supplies 4.5 million biopharmaceutical jobs to American...   Read More

Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.

By Jay Taylor  |    April 25, 2017
Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow’s breakthrough treatments and cures,...   Read More

New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need

By Lucy Vereshchagina  |    April 17, 2017
In an exciting step forward to support research and development of innovative new medicines and devices for pediatric patients, the Critical Path Institute (C-Path) announced the launch of a new...   Read More

PhRMA urges USTR to protect American innovators abroad

By Mark Grayson  |    February 10, 2017
Yesterday, PhRMA submitted comments for the 2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates